Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001373604-25-000007·Aclaris Therapeutics, Inc.
Schedule 13G ownership disclosure
Aclaris Therapeutics Inc
Common Stock, $0.00001 par value · CUSIP: 00461U105
Event date: 2024-12-31
- Filing-level shares
- 14,250,000
- Percent of class
- 13.3%
- BML Investment Partners, L.P.
Shares: 14,250,000 · Class: 13.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001373604-25-000007
- Form type
- SCHEDULE 13G/A
- Filer
- Aclaris Therapeutics, Inc.
- CIK
- CIK 1557746
- Filed
- Feb 13, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership